Biogen Stock News

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript d

Biogen (BIIB) and Catalyst Biosciences (CBIO) have ended their collaboration on potential treatments for dry AMD (dAMD), a leading cause of blindness.Per the terms of the agreement,…

Risk-averse investors have been shunning small-cap stocks, but look for the clouds to clear soon over this asset class, says a fund manager at Artemis.

Patients who received Biogen''s Alzheimer''s drug for over two years showed slower cognitive decline — leading Biogen stock to tick higher.

Biogen (BIIB) is trading ~3% higher in the pre-market Wednesday after announcing long-term data from two Phase 3 trials for the Alzheimer’s therapy Aduhelm developed in partnership with…

CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM® (aducanumab

ADUHELM continued to reduce two key Alzheimer''s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half years Data from both Phase 3 studies also show that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks These data further inform the scientific evidence for amyloid as a surrogate biomarker and the importance of continuation of treatment CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB ) announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM ® (aducanumab-avwa) injection 100 mg/mL for intravenous use, patients in the long-term extension phase of the Phase 3 trials continued to experience significant reductions in two key Alzheimer''s disease pathologies, amyloid beta plaques and plasma p-tau181. The data also show that in both Phase 3 trials, at 78 weeks, patients with reduced levels of plasma p-tau181 had less clinical decline than those whose plasma p-tau181 levels were not reduced.

SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO ) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the treatment of dry AMD (dAMD). Under the terms of the agreement, Biogen has returned the rights for further development on CB 2782-PEG and has ended the collaboration on other potential AMD treatments. "We are delighted to regain the rights to CB 2782-PEG which unlocks the full potential of our complement proteases in ophthalmology. We now have two wholly-owned, potentially best-in-class development candidates, CB 2782-PEG and CB 4332, a long half-life complement factor I fusion, each targeting clinically validated mechanisms in dry AMD. Dry AMD, a leading cause of blindness in its severe form for which there are no currently approved drugs, represents a significant market opportunity, estimated at over $10B," said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences. About Catalyst Biosciences, the Protease Medicines …

Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM rather than sharing global profits and […] The post Japan – Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments appeared first on Webnewswire .

Eisai Co Ltd (OTC: ESALY ) is giving up its right to share in profits from Aduhelm (aducanumab-avwa), which was developed in partnership with Biogen Inc (NASDAQ: BIIB ). Biogen and Eisai have amended their agreement to give Biogen full authority to make regulatory and sales decisions regarding Aduhelm. From 2023, Eisai will receive royalties starting at 2% … Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB) said the Ph

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Discontinues Phase 2 Study Of Imsidolimab In Acne Anaptys Bio, Inc. (NASDAQ: ANAB ) said the Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. The study will be discontinued. "Although the results of this ACORN trial are disappointing, I would like to thank all of the patients, investigators, staff and our employees involved in conducting this trial," said Hamza Suria , AnaptysBio''s CEO. "We look forward to further advancement of imsidolimab for the treatment of GPP and hidradenitis suppurativa. AnaptysBio continues to utilize its strong cash position in a capital-efficient manner to advance three wholly-owned clinical-stage programs with $90 to $100 million anticipated net cash burn in 2022." The stock was declining 10.48% to $25.46 in premarket trading. Biogen, Eisai Amend Economic Agreement Related To Aduhelm Biogen, Inc. (NASDAQ: BIIB ) and Eisai Co.

Biogen (BIIB) and Eisai (ESALY) (ESALF) amended their collaboration agreement on Alzheimer''s therapy Aduhelm (aducanumab) giving sole global commercialization rights to…

TOKYO, Mar 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer''s disease collaboration agreement with Biogen Inc. separately announced today. Effective as of January 1, 2023, Eisai will receive a tiered royalty on net sales of ADUHELM rather than sharing global profits and losses. The details of the royalty rates are … Full story available on Benzinga.com

CAMBRIDGE, Mass. and TOKYO, March 14, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today that the companies have amended their existing collaborat